Red Cell Agglutinability affected by Disease

Stratton, F.; Renton, P. H.; Hancock, Jeanne A.

doi:10.1038/181062a0

Cited by 70 publications

(38 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anti-Wra has often been observed together with other blood group antibodies, particularly with anti-E [4], but also with anti-D, anti-C or anti-D-f-C [4], anti-Cx [10,11], anti-E and anti-Mia [9], anti-D-j-C+E and anti-Mia [9], anti-f [cit. 4], anti-Y [3], anti-K [8], and with anti-S and anti-Mia [14]. In our laboratory we have searched for anti-Wra in five samples of anti-E, one anti-D-|-E, one anti-E+ c, one anti-E -f anti-K, four anti-c, two anti-Cw, and six anti-K. One of the anti-Cw sera, both of which were "naturally occurring" [7], also contained a potent anti-Wra.…”

Section: Materials and Resultsmentioning

confidence: 99%

Some Observations on the Wright Blood Group System

Kornstad¹

1961

Vox Sanguinis

View full text Add to dashboard Cite

Section: Materials and Resultsmentioning

confidence: 99%

Some Observations on the Wright Blood Group System

Kornstad¹

1961

Vox Sanguinis

View full text Add to dashboard Cite

“…In den folgenden Jahren wurden eine Reihe weiterer Fälle von erworbener Abschwächung oder Verlust der AB0-Antigene berichtet: Diese betrafen nicht nur das A-Antigen [z.B. [10][11][12], sondern auch das B-Antigen [13,14]. In einem Fall waren bei einer Person der Blutgruppe AB sogar die beiden Antigene A und B unabhängig voneinander betroffen, so daß gleichzeitig 4 verschiedene Erythrozytenpopulationen (AB, A, B und 0) im Patientenblut gefunden werden konnten [15].…”

Section: Die Erworbene Abschwächung Der Ab0-antigeneunclassified

“…9, 14, 16, 18, 19], chronischer lymphatischer Leukämie [13,21], akuter monoblastärer Leukämie [12], Eosinophilenleukämie [15] und Erythroleukämie [22,23] [9]. Der Nachweis des abgeschwächten Antigens kann gegebenenfalls durch eine Adsorptions-Elutions-Untersuchung bestätigt werden [9,11,12,14]. Durch Enzymbehandlung der Patientenerythrozyten (z.B.…”

Section: Die Erworbene Abschwächung Der Ab0-antigeneunclassified

Erworbene Veränderungen der erythrozytären AB0-Merkmale

Strobel¹

2000

Transfus Med Hemother

View full text Add to dashboard Cite

Objective: Pathological changes of the ABO antigens on red blood cells are rare events, but they are important in blood group serology because of the risk of false results in ABO typing. This review is designed to show these pathological changes and the problems in ABO testing caused by them, especially if monoclonal reagents are used. Sources: Selected literature and own experiences. Results: The most relevant pathological changes of the ABO antigens are: 1) The depression of the A- and/or B-antigen on some or (nearly) all red blood cells of some patients with leukemia or myeolodysplastic syndrome. This change is caused by a reduced activity of ABH glycosyltransferases. 2) The acquired B-antigen in some pa-tients with gastrointestinal diseases and/or bacteremia. It is caused by a deacetylation of the A-antigen leading to a B-like antigen. 3) The ‘acquired A-like antigen’ in cases of Tn polyagglutinability which is caused by the cross-reactivity of some anti-A reagents with the Tn antigen. It has been found in cases of leukemia, but also in healthy persons. Conclusions: Although reagents of high quality are used for ABO typing, testing for ABO isoantibodies in the serum is still indispensable. Monoclonal antibodies that are cross-reactive with the acquired B-antigen or with Tn-positive red blood cells should not be used for ABO typing.

show abstract

“…Appropriate laboratory procedures were, however, undertaken to exclude other causes of dcpigmenlation in addition to history and clinical examination. The blood grouping of these patients were carried out in outpatients, while the secretion of blood group substances in saliva was determined by the method of Stratton and Renton (1958) in the Department of Pathology.All the patients were given treatment with the photosensitizer i.e. macsoralcn capsules (10 mg) one capsule daily at 6 o'clock in the morning followed by local application of macsoralcn lotion on the vitiligenous areas at 8 o'clock.…”

mentioning

confidence: 99%